Compare Core Scientific Inc (CORZ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Sanofi SA — how do they compare? Core Scientific Inc trades at $20.75 (market cap $6.35B), while Sanofi SA trades at $43.38 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 16.4× Core Scientific Inc's market cap, and Sanofi SA pays a 5.55% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| CORZ | SNY | |
|---|---|---|
Market Cap | $6.35B | $104.30B |
Sector | Technology | Health |
52-Week High | $29.16 | $52.34 |
52-Week Low | $13.55 | $41.33 |
Enterprise Value | $8.88B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $20.87, up 7.36% today, amid strong analyst support with 19 buy ratings and a $35.88 consensus price target. The stock shows bearish technical signals with resistance at $21, while fundamentals reveal significant losses (-$288.62M net income in 2025) despite revenue growth to $319M. Recent AMD partnership for 2.5GW data center capacity signals strategic pivot to AI infrastructure.
Outlook balances high growth potential from AI contracts against substantial cash burn and negative margins. Key risks include execution of expansion plans and profitability timeline, but institutional interest and analyst optimism suggest upside if operational targets are met.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
